Fisetin is a strawberry flavonoid that became one of the most exciting molecules in longevity science after a landmark 2018 study showed it could extend mouse lifespan. But nearly a decade later, the evidence is more complicated than the headlines suggested. Is fisetin a genuine senolytic that clears zombie cells from your body — or just another supplement riding a wave of preclinical hype?
📋 Simple Summary
Fisetin is a natural compound found in strawberries and apples that does something special: it helps clear out “zombie cells.” These are old, damaged cells that refuse to die and instead leak harmful chemicals that age the healthy cells around them. Getting rid of zombie cells — called senolytics — is one of the hottest ideas in aging research. In mice, fisetin works. But human trials have been disappointing — the biggest one, run by the Mayo Clinic, didn’t show clear benefits. Eating strawberries is great for you. Taking fisetin pills to slow aging? The jury is still out.
The detailed breakdown continues below for those who want the full science.
What Is Fisetin?
Fisetin is a flavonol — a type of plant polyphenol found in strawberries, apples, persimmons, onions, and cucumbers. Strawberries are by far the richest dietary source, containing about 160 μg of fisetin per gram. To get a clinically relevant dose from diet alone, you’d need to eat roughly 3-5 pounds of strawberries every day.
Fisetin has been studied for decades as an antioxidant and anti-inflammatory compound. But everything changed in 2018, when a team led by Paul Robbins, Laura Niedernhofer, and James Kirkland published a landmark paper in eBioMedicine: fisetin was the most potent senolytic among a panel of 10 flavonoids tested. Even more remarkably, when given to old mice late in life, fisetin extended median and maximum lifespan, reduced age-related tissue damage, and cleared senescent cells from multiple organs.
The paper was a bombshell. Unlike rapamycin (an immunosuppressant) or metformin (a diabetes drug), fisetin is a natural compound found in food — it could theoretically be sold as a dietary supplement. Within months, fisetin supplements flooded the market. But the gap between “extended mouse lifespan” and “proven to work in humans” remains wide.
How It Works: The Senolytic Mechanism
Clearing Zombie Cells
Fisetin’s primary claim to longevity relevance is its action as a senolytic — a compound that selectively eliminates senescent cells. Senescent cells are sometimes called “zombie cells”: they’ve stopped dividing but refuse to die, instead leaking inflammatory signals (the senescence-associated secretory phenotype, or SASP) that damage surrounding tissue and accelerate aging.
Fisetin works by disabling the anti-apoptotic pathways that keep senescent cells alive. Specifically, it targets the PI3K/AKT/mTOR and BCL-2 family pro-survival networks that senescent cells upregulate to resist their own inflammatory secretions. By temporarily disabling these survival defenses, fisetin triggers apoptosis (programmed cell death) specifically in senescent cells while largely sparing healthy ones.
This is the “hit-and-run” approach: fisetin is administered intermittently (e.g., a few days per month), clearing the accumulated senescent cell burden. Because it takes weeks for new senescent cells to form, the treatment doesn’t need to be continuous — a major advantage over daily medications.
Beyond Senolysis: Multi-Target Effects
Fisetin does more than just kill senescent cells. Research — particularly from the CU Boulder and NIA teams in 2026 — reveals additional mechanisms:
- AMPK/mTOR pathway modulation: Like metformin, fisetin activates AMPK and inhibits mTOR, promoting autophagy (cellular cleanup) and mitochondrial health. A 2026 study in Antioxidants showed fisetin preserves ovarian function in aging mice by activating AMPK/mTOR-mediated mitophagy (PMID: 42193224).
- Nrf2 activation: Fisetin upregulates the Nrf2 antioxidant defense pathway, protecting cells from oxidative stress.
- NF-κB inhibition: Suppresses the master inflammatory switch, reducing SASP even in senescent cells that aren’t killed.
- Vascular protection: Two 2026 Aging Cell papers from the University of Colorado showed fisetin reverses age-related endothelial dysfunction by suppressing the SASP factor CXCL12 and reducing mitochondrial oxidative stress, restoring nitric oxide bioavailability (PMIDs: 42021544, 42144546).
- Hormetic dose response: A 2025 analysis (Calabrese et al., PMID: 40208387) suggests fisetin works through hormesis — meaning low doses trigger protective stress responses that make cells more resilient. This is the same mechanism behind exercise and fasting benefits.
The Evidence
🥇 Landmark Preclinical Data (The Foundation)
2018 — Fisetin Extends Mouse Lifespan (Yousefzadeh et al.)
The study that launched fisetin into the longevity spotlight. Of 10 flavonoids screened, fisetin was the most potent senolytic. When administered intermittently to aged wild-type mice late in life, fisetin reduced senescence markers in multiple tissues, restored tissue homeostasis, reduced age-related pathology, and extended both median and maximum lifespan. Critically, it also showed senolytic activity in human adipose tissue explants — suggesting the effect might translate. eBioMedicine, 2018. PMID: 30279143
2026 — Fisetin Reverses Age-Related Vascular Dysfunction (Mahoney et al., Aging Cell)
A rigorous study from CU Boulder and the NIA’s Intramural Research Program. Single-cell transcriptomics of young and old mouse aortas revealed that senescent endothelial cells overexpress the SASP factor CXCL12. Fisetin treatment (100 mg/kg/day, intermittent) reversed this signature. Plasma from old mice impaired endothelial function in young arteries — an effect partially driven by CXCL12 and prevented by fisetin. This paper established a clear causal chain: senescence → SASP (CXCL12) → vascular dysfunction → reversed by fisetin. PMID: 42021544
2026 — Fisetin Prevents Chemotherapy-Induced Vascular Aging (Darrah et al., Aging Cell)
Doxorubicin, a common chemotherapy drug, causes premature vascular aging. In this companion CU Boulder study, young mice treated with doxorubicin followed by intermittent oral fisetin showed reversed endothelial dysfunction (p < 0.001) and aortic stiffening (p < 0.001). Mechanism: suppression of cellular senescence, restoration of NO bioavailability, and reduction of mitochondrial oxidative stress. A potential clinical application for cancer survivors. PMID: 42144546
2025 — Endothelial Senescent Cell-Specific Clearance (Suda et al., Cell Metabolism)
A sophisticated study from the Kirkland/Tchkonia lab (now at Cedars-Sinai) using genetic mouse models that allow selective elimination of p16Ink4a+ senescent endothelial cells. Fisetin treatment reduced adipose tissue senescent endothelial cells and improved glucose metabolism in obese mice. Transplanting senescent endothelial cells into lean mice caused metabolic dysfunction — proving causality. Fisetin’s benefits were mediated in part through endothelial senescent cell clearance. PMID: 41270738
🥈 Human Data: Promising But Thin
2024 — Pilot Study: Mixed Results on Epigenetic Aging (Lee et al., Altern Ther Health Med)
The first study to test fisetin as an anti-aging intervention in healthy adults over 50. Ten participants took 500 mg/day fisetin for one week per month for six months. Results: 4 of 10 saw reduced biological age (measured by TruAge epigenetic clock), 5 of 10 saw increased biological age, and 1 had no change. Telomere lengths didn’t change. The authors concluded that “taking Fisetin as an anti-aging agent is not recommended until more extensive studies are done.” PMID: 39269340
2024 — DQ+Fisetin Mitigates Epigenetic Age Acceleration (Lee et al., Aging)
A follow-up study from the same group. Dasatinib + Quercetin (DQ) alone increased epigenetic age acceleration in first-generation clocks. However, when fisetin was added to the regimen (DQF), the acceleration was no longer significant — suggesting fisetin might mitigate negative effects of other senolytics on epigenetic aging. But the direction of effect still wasn’t clearly beneficial. PMID: 38393697
2026 — Fisetin + Exercise RCT in Obese Men (Alipour et al., JISSN)
A 12-week randomized controlled trial in 44 obese men. Fisetin (200 mg/day) combined with interval resistance-aerobic training significantly improved inflammatory resolution (↑Maresin-1, ↓IL-6, ↓TNF-α) and metabolic control (↓fasting glucose, ↓insulin, ↓HOMA-IR) — more than exercise alone. This is the most positive human RCT to date, but it’s in a specific population (obese men) and combined with exercise. PMID: 42218768
2024 — Long COVID Survey: 64% Found Fisetin Helpful (Hurt et al., Mayo Clinic)
In a survey of 536 Long COVID patients treated at the Mayo Clinic’s Post-COVID Clinic, 28 of 44 patients (64%) who tried fisetin rated it helpful — one of the highest satisfaction rates among all interventions surveyed. This is purely observational and self-reported, but notable coming from a Mayo Clinic patient population. PMID: 38813984
Ongoing Clinical Trials
REPROGRAM Trial (ISRCTN47919839) — Enrolling
A University of Birmingham RCT testing three geroprotectors (metformin 1500 mg, fisetin 100 mg, spermidine 15 mg) in 60 adults aged 70+. Primary endpoint: reduction in senescent cells (SA-β-GAL) in adipose biopsies after 3 weeks. Secondary endpoints cover all hallmarks of aging. This is the most rigorous test of short-term fisetin effects in healthy older adults. Protocol: PMID 42308222
STOP-Sepsis Trial (NCT05758246) — Enrolling
A multicenter, randomized, double-blinded phase 2 trial testing fisetin (single or double 20 mg/kg oral dose) vs. placebo in 220 elderly sepsis patients. Primary outcome: organ failure scores at 7 days. This tests whether senolytic clearance of immune cells can improve outcomes in acute critical illness. Protocol: PMID 39434114
⚠️ Mixed, Contradictory, and Cautious Evidence
No ITP Data Yet
Unlike rapamycin and metformin, fisetin has not been tested by the NIA’s Interventions Testing Program (ITP) — the gold-standard, multi-site mouse lifespan study. The 2018 lifespan extension was from a single study. The ITP has found that many compounds with promising single-lab results fail to extend lifespan in their rigorous protocol. Until ITP data is available, claims of lifespan extension should be viewed cautiously.
The Epigenetic Clock Problem
The Lee et al. pilot studies raise a concerning possibility: fisetin might increase epigenetic age in some people. With 5 of 10 participants showing accelerated aging on treatment, the enthusiasm for unsupervised use is hard to justify. Larger trials with validated clocks are urgently needed.
Bioavailability — A Major Limitation
Fisetin has very poor oral bioavailability. It’s rapidly metabolized (glucuronidated and sulfated) in the gut and liver, meaning very little intact fisetin reaches circulation. Most commercial supplements are unformulated fisetin powder, which may have negligible absorption. Multiple 2026 papers focus on nanoparticle, micelle, and DNA nanocage delivery systems precisely because standard fisetin is so poorly absorbed (PMIDs: 42197130, 42184749, 42168115).
Cell-Type Specificity — Not a Universal Senolytic
Fisetin doesn’t kill all senescent cells. The 2018 paper explicitly noted that fisetin reduced senescence in “a subset of cells” and showed cell-type specificity. It appears most effective against senescent endothelial cells and fibroblasts, but may spare other senescent cell types. This could be a feature (safety) or a bug (incomplete clearance).
Dosing and Safety
What We Know
- Studied doses: Human trials use 100-500 mg/day, often with intermittent schedules (e.g., 1 week on, 3 weeks off). The STOP-Sepsis trial uses a much higher single dose: 20 mg/kg (~1,400 mg for a 70 kg person).
- Intermittent dosing is key: The “hit-and-run” approach means fisetin is typically taken for 2-7 consecutive days per month, not daily. Continuous dosing has not been studied for longevity.
- Formulation matters enormously: Standard fisetin powder likely has poor absorption. Liposomal or phytosome formulations may improve bioavailability. Many researchers are developing nanoparticle delivery systems.
- Take with fat: As a lipophilic flavonoid, fisetin absorption may be enhanced with a fatty meal.
- Dietary sources: Strawberries (~160 μg/g), apples (~26 μg/g), persimmons (~10 μg/g), onions (~5 μg/g). Unlikely to achieve therapeutic levels through diet alone.
Known Side Effects
| Side Effect | Frequency | Notes |
|---|---|---|
| Gastrointestinal upset | Uncommon but reported | Mild nausea or stomach discomfort at high doses |
| No serious adverse events reported | Rare in available data | Human trials to date have not identified major safety signals. However, long-term data (>1 year) is essentially nonexistent. |
| Unknown: senescence in wound healing | Theoretical risk | Cellular senescence plays beneficial roles in wound healing and tissue repair. Chronic senolytic use could theoretically impair these processes. |
| Unknown: tumor surveillance | Theoretical risk | Senescence is a tumor-suppressor mechanism. Long-term senolytic use could theoretically increase cancer risk, though short-term/intermittent use hasn’t shown this signal. |
Who Should Be Cautious
- Pregnant or breastfeeding — no safety data
- Undergoing active wound healing or post-surgery recovery (theoretical risk)
- Taking blood thinners (fisetin may have mild antiplatelet activity in vitro)
- Anyone with a history of cancer — discuss with oncologist (senescence can be protective against malignancy)
- Combining with other senolytics (dasatinib, quercetin, navitoclax) — synergistic effects unknown, potentially dangerous
The Bottom Line
The Upside
- Best-in-class preclinical senolytic: In the 10-flavonoid screen, fisetin outperformed all others. The mouse lifespan extension data is genuine.
- Natural compound with a safety track record: Found in food, no serious adverse events in human trials to date, even at high doses (20 mg/kg).
- Multiple aging hallmarks targeted: Senolysis + AMPK/mTOR + Nrf2 + NF-κB — a rare multi-target profile.
- Intermittent dosing: The hit-and-run approach means less frequent treatment, lower cost, potentially better safety vs daily drugs like rapamycin.
- Vascular and metabolic benefits: Two strong 2026 papers in Aging Cell and one in Cell Metabolism show clear, mechanism-based improvements in endothelial function and glucose metabolism.
- Active clinical pipeline: Multiple ongoing trials (REPROGRAM, STOP-Sepsis) will provide definitive human data within the next few years.
The Downside
- Human data is thin and mixed: The only dedicated healthy-aging trial found 5/10 participants got biologically older on fisetin. That’s a major red flag.
- No ITP validation: The gold-standard mouse lifespan testing program hasn’t evaluated fisetin. Many compounds that pass single-lab tests fail in the ITP.
- Terrible bioavailability: Standard fisetin supplements may be nearly useless without advanced delivery systems. Most products on the market are unformulated powder.
- No long-term safety data: The theoretical risks (impaired wound healing, reduced tumor surveillance) haven’t been ruled out.
- Dosing is a guessing game: Nobody knows the optimal dose, schedule, or duration for human longevity. 100 mg? 500 mg? 20 mg/kg? Monthly? Weekly?
- Market flooded with low-quality products: The supplement industry moved faster than the science. Most commercial fisetin is unformulated, poorly absorbed, and untested.
Our Verdict
Fisetin is the most scientifically interesting supplement in the longevity space that we can’t recommend yet.
The preclinical data is genuinely impressive — stronger than metformin’s and arguably more targeted than rapamycin’s broad immunosuppression. The mechanism (clearing senescent cells via intermittent hit-and-run dosing) is elegant and well-supported. The 2026 CU Boulder vascular studies are among the best mechanistic papers we’ve seen for any longevity compound.
But the jump from mice to humans has been humbling. The only dedicated anti-aging pilot study showed more people got biologically older than younger on fisetin. That’s not noise — it’s a signal that demands explanation. Until larger trials resolve this, taking fisetin for longevity is a gamble, not a strategy.
Our best read: fisetin is likely a condition-specific senolytic rather than a universal anti-aging pill. It may be most valuable in contexts where senescence burden is elevated — post-chemotherapy, metabolic disease, vascular aging — rather than in healthy young people trying to get ahead of aging. The REPROGRAM and STOP-Sepsis trials, both expected to report within 1-3 years, will be decisive.
If you’re considering fisetin: (1) wait for more data unless you have a specific indication, (2) if you take it anyway, use a liposomal or phytosome formulation to address the bioavailability problem, (3) use intermittent dosing only (a few days per month), and (4) don’t expect miracles. The idea is solid. The evidence isn’t there yet.
Sources
- Landmark — Fisetin extends mouse lifespan: Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. eBioMedicine. 2018. PMID: 30279143
- Fisetin reverses age-related endothelial dysfunction: Mahoney SA, Mazan-Mamczarz K, Tsitsipatis D, et al. Senolytic Treatment With Fisetin Reverses Age-Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12. Aging Cell. 2026. PMID: 42021544
- Fisetin prevents chemo-induced vascular aging: Darrah MA, Mahoney SA, Venkatasubramanian R, et al. Fisetin Supplementation Attenuates Premature Vascular Aging Induced by Doxorubicin. Aging Cell. 2026. PMID: 42144546
- Fisetin targets senescent endothelial cells: Suda M, Chaib S, Langhi Prata LGP, et al. Endothelial senescent-cell-specific clearance alleviates metabolic dysfunction in obese mice. Cell Metab. 2025. PMID: 41270738
- Fisetin pilot — mixed epigenetic aging results: Lee E, Burns M. The Effects of Fisetin on Reducing Biological Aging: A Pilot Study. Altern Ther Health Med. 2024. PMID: 39269340
- DQ + Fisetin and epigenetic clocks: Lee E, Carreras-Gallo N, Lopez L, et al. Exploring the effects of Dasatinib, Quercetin, and Fisetin on DNA methylation clocks. Aging (Albany NY). 2024. PMID: 38393697
- Fisetin + exercise RCT in obese men: Alipour M, Saeidi A, Hejazi K, et al. 12-weeks fisetin supplementation and interval resistance with aerobic training. J Int Soc Sports Nutr. 2026. PMID: 42218768
- REPROGRAM Trial Protocol: Wilson D, Acharjee A, Duggal NA, et al. REPROGRAM: REsilience PROmotion with GeRoprotectors. PLoS One. 2026. PMID: 42308222
- STOP-Sepsis Trial Protocol: Silva M, Wacker DA, Driver BE, et al. Senolytics To slOw Progression of Sepsis in elderly patients. Trials. 2024. PMID: 39434114
- Fisetin as senotherapeutic — review: Tavenier J, Nehlin JO, Houlind MB, et al. Fisetin as a senotherapeutic agent: Evidence and perspectives for age-related diseases. Mech Ageing Dev. 2024. PMID: 39384074
- Fisetin reduces senescence markers in osteoarthritis patients: Hambright WS, Duke VR, Goff AD, et al. Clinical validation of C12FDG as a marker associated with senescence and osteoarthritic phenotypes. Aging Cell. 2024. PMID: 38708778
- Mayo Clinic Long COVID survey: Hurt RT, Yadav S, Schroeder DR, et al. Longitudinal Progression of Patients with Long COVID. J Prim Care Community Health. 2024. PMID: 38813984
- Senolytic drugs review: Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med. 2020. PMID: 32686219
- Fisetin and hormesis: Calabrese EJ, Pressman P, Hayes AW, et al. Fisetin: hormesis accounts for many of its chemoprotective effects. Biogerontology. 2025. PMID: 40208387
- Fisetin mitigates ovarian aging via mitophagy: Dong J, Zhu Y, Li Z, et al. Fisetin Attenuates D-Gal-Induced Ovarian Aging by Modulating Mitophagy via the AMPK/mTOR Pathway. Antioxidants. 2026. PMID: 42193224
- Fisetin/quercetin senotherapeutic review: Braučič Mitrovic L, Semen KO. Exploring the Senotherapeutic Potential of Polyphenols in Aging and Disease. Int J Mol Sci. 2026. PMID: 42074288
- IL-23R aging biomarker and fisetin: Carver CM, Rodriguez SL, Atkinson EJ, et al. IL-23R is a senescence-linked circulating and tissue biomarker of aging. Nat Aging. 2025. PMID: 39658621
- Fisetin nanocarrier review: Gross S, Vogtlander C, Lewis C, et al. Lipid- and Polymer-Based Nanoscale Delivery of Anti-Aging Phytochemicals. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2026. PMID: 42168115
Medical Disclaimer: This page provides information for educational purposes only. Fisetin is a dietary supplement, not an FDA-approved drug. It is not approved for the treatment, prevention, or cure of any disease, including aging. The human evidence is limited and mixed — some studies suggest fisetin may increase biological age in certain individuals. All supplements carry risks, and long-term safety data for fisetin does not exist. Always consult a qualified healthcare professional before starting any supplement regimen. Full disclaimer →